Early Repetitive Transcranial Magnetic Stimulation Exerts Neuroprotective Effects and Improves Motor Functions in Hemiparkinsonian Rats.
Animals
Corpus Striatum
/ metabolism
Disease Models, Animal
Dopaminergic Neurons
/ metabolism
Gait
/ physiology
Male
Motor Cortex
/ metabolism
Motor Skills
/ physiology
Neuroprotection
/ physiology
Oxidopamine
Parkinson Disease, Secondary
/ chemically induced
Rats
Rats, Wistar
Transcranial Magnetic Stimulation
/ methods
Tyrosine 3-Monooxygenase
/ metabolism
Journal
Neural plasticity
ISSN: 1687-5443
Titre abrégé: Neural Plast
Pays: United States
ID NLM: 100883417
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
06
2021
revised:
31
10
2021
accepted:
13
12
2021
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
25
3
2022
Statut:
epublish
Résumé
Repetitive transcranial magnetic stimulation (rTMS) is a popular noninvasive technique for modulating motor cortical plasticity and has therapeutic potential for the treatment of Parkinson's disease (PD). However, the therapeutic benefits and related mechanisms of rTMS in PD are still uncertain. Accordingly, preclinical animal research is helpful for enabling translational research to explore an effective therapeutic strategy and for better understanding the underlying mechanisms. Therefore, the current study was designed to identify the therapeutic effects of rTMS on hemiparkinsonian rats. A hemiparkinsonian rat model, induced by unilateral injection of 6-hydroxydopamine (6-OHDA), was applied to evaluate the therapeutic potential of rTMS in motor functions and neuroprotective effect of dopaminergic neurons. Following early and long-term rTMS intervention with an intermittent theta burst stimulation (iTBS) paradigm (starting 24 h post-6-OHDA lesion, 1 session/day, 7 days/week, for a total of 4 weeks) in awake hemiparkinsonian rats, the effects of rTMS on the performance in detailed functional behavioral tests, including video-based gait analysis, the bar test for akinesia, apomorphine-induced rotational analysis, and tests of the degeneration level of dopaminergic neurons, were identified. We found that four weeks of rTMS intervention significantly reduced the aggravation of PD-related symptoms post-6-OHDA lesion. Immunohistochemically, the results showed that tyrosine hydroxylase- (TH-) positive neurons in the substantia nigra pars compacta (SNpc) and fibers in the striatum were significantly preserved in the rTMS treatment group. These findings suggest that early and long-term rTMS with the iTBS paradigm exerts neuroprotective effects and mitigates motor impairments in a hemiparkinsonian rat model. These results further highlight the potential therapeutic effects of rTMS and confirm that long-term rTMS treatment might have clinical relevance and usefulness as an additional treatment approach in individuals with PD.
Identifiants
pubmed: 34987572
doi: 10.1155/2021/1763533
pmc: PMC8723880
doi:
Substances chimiques
Oxidopamine
8HW4YBZ748
Tyrosine 3-Monooxygenase
EC 1.14.16.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1763533Subventions
Organisme : NICHD NIH HHS
ID : P50 HD105351
Pays : United States
Informations de copyright
Copyright © 2021 Tsung-Hsun Hsieh et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest regarding the publication of this paper.
Références
JAMA. 2014 Apr 23-30;311(16):1670-83
pubmed: 24756517
Eur J Neurosci. 2012 Sep;36(5):2669-78
pubmed: 22693966
Brain Stimul. 2020 May - Jun;13(3):655-663
pubmed: 32289694
PLoS One. 2015 Oct 02;10(10):e0139892
pubmed: 26431529
Neurophysiol Clin. 2015 Nov;45(4-5):371-88
pubmed: 26319759
Eur J Neurosci. 2007 Jan;25(2):397-405
pubmed: 17284180
Neurosci Lett. 2016 Aug 15;628:1-9
pubmed: 27268039
Cereb Cortex. 2013 Jul;23(7):1593-605
pubmed: 22661405
Mol Med Rep. 2018 Feb;17(2):3356-3363
pubmed: 29257290
Lancet Neurol. 2006 Jun;5(6):525-35
pubmed: 16713924
Nat Neurosci. 2018 Oct;21(10):1370-1379
pubmed: 30250265
Parkinsonism Relat Disord. 2019 Sep;66:3-8
pubmed: 31300260
Ann Neurol. 2018 Dec;84(6):797-811
pubmed: 30357892
Clin Neurophysiol. 2007 Jan;118(1):140-5
pubmed: 17097343
Mov Disord. 2007 May 15;22(7):1046-50
pubmed: 17575584
Neurosci Lett. 2007 Aug 9;423(1):12-7
pubmed: 17644250
J Neurol Sci. 2010 Apr 15;291(1-2):1-4
pubmed: 20153482
Neurology. 2013 Apr 9;80(15):1400-5
pubmed: 23516319
Neurorehabil Neural Repair. 2012 Nov-Dec;26(9):1096-105
pubmed: 22593114
Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S3-8
pubmed: 19131039
Exp Neurol. 2002 Jun;175(2):303-17
pubmed: 12061862
Mov Disord. 2007 Jul 30;22(10):1518-1519
pubmed: 17516472
Prog Neurobiol. 2015 Nov;134:104-21
pubmed: 26455457
J Parkinsons Dis. 2013 Jan 1;3(3):255-69
pubmed: 23948989
J Neurophysiol. 2012 Feb;107(3):966-72
pubmed: 22013238
Neurosci Lett. 2020 Feb 6;719:133437
pubmed: 29476796
J Mater Sci Mater Med. 2014 Jan;25(1):217-27
pubmed: 24072390
Behav Brain Res. 2011 Sep 12;222(1):1-9
pubmed: 21435355
J Parkinsons Dis. 2017;7(2):235-245
pubmed: 28505983
Clin Neurophysiol. 2006 Dec;117(12):2584-96
pubmed: 16890483
Clin Neurophysiol. 2004 Nov;115(11):2530-41
pubmed: 15465443
Clin Geriatr Med. 1996 Nov;12(4):825-45
pubmed: 8890118
Clin Neurophysiol. 2005 Feb;116(2):244-53
pubmed: 15661100
Mov Disord. 2017 Jul;32(7):1035-1046
pubmed: 28394013
Clin Neurophysiol. 2020 Feb;131(2):474-528
pubmed: 31901449
J Neurol. 2015 Feb;262(2):357-64
pubmed: 25385053
Brain Sci. 2020 Apr 01;10(4):
pubmed: 32244769
J Rehabil Med. 2016 Oct 12;48(9):824-828
pubmed: 27670977
Clin Neurophysiol. 2017 Nov;128(11):2318-2329
pubmed: 29040922
Mov Disord. 2006 Mar;21(3):325-31
pubmed: 16211618
World Neurosurg. 2016 May;89:628-635.e1
pubmed: 26704203
J Neurol Sci. 2004 Jan 15;217(1):73-81
pubmed: 14675613
Eur J Neurol. 2003 Sep;10(5):567-72
pubmed: 12940840
J Neuroinflammation. 2016 Jun 14;13(1):150
pubmed: 27301743
Mov Disord. 2014 Nov;29(13):1666-74
pubmed: 25220042
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Brain Stimul. 2020 Nov - Dec;13(6):1580-1587
pubmed: 32949780
Neuron. 2005 Jan 20;45(2):201-6
pubmed: 15664172
Behav Brain Res. 2006 Apr 25;169(1):1-9
pubmed: 16413939
Neuropharmacology. 2002 Jul;43(1):101-9
pubmed: 12213264
Neuroreport. 2010 Mar 10;21(4):268-72
pubmed: 20087233
Med Biol Eng Comput. 2012 Sep;50(9):937-46
pubmed: 22707230
Clin Neurophysiol. 2007 Jan;118(1):131-9
pubmed: 17097342
Mov Disord. 2009 Feb 15;24(3):357-63
pubmed: 18972549
J Neurosci. 2001 Aug 1;21(15):RC157
pubmed: 11459878
Mov Disord. 2008 Jan 30;23(2):207-11
pubmed: 17999422
Restor Neurol Neurosci. 2014;32(6):743-53
pubmed: 25079979
N Engl J Med. 2006 Aug 31;355(9):896-908
pubmed: 16943402
Parkinsons Dis. 2019 Jun 4;2019:2196195
pubmed: 31275542
J Neurosci. 2010 Oct 20;30(42):14182-93
pubmed: 20962239
Stereotact Funct Neurosurg. 2005;83(5-6):222-7
pubmed: 16534254
Mov Disord. 2006 Dec;21(12):2201-5
pubmed: 17219616
Ageing Res Rev. 2014 Mar;14:19-30
pubmed: 24503004
Eur J Pharmacol. 1977 Feb 21;41(4):361-7
pubmed: 557411
Front Neurol. 2020 Dec 21;11:584374
pubmed: 33408684
Exp Brain Res. 2008 May;187(3):467-75
pubmed: 18320180
Clin Neurol Neurosurg. 2013 Jul;115(7):887-91
pubmed: 22980521
Brain Stimul. 2013 Nov;6(6):884-91
pubmed: 23769414
Brain Res. 1993 Oct 29;626(1-2):167-74
pubmed: 8281427
Parkinsonism Relat Disord. 2009 Sep;15(8):587-91
pubmed: 19403325
Mov Disord. 2016 Aug;31(8):1122-4
pubmed: 27324696
J Parkinsons Dis. 2019;9(1):17-29
pubmed: 30741691
Eur J Neurosci. 2005 Aug;22(3):735-44
pubmed: 16101755
Praxis (Bern 1994). 2016 Mar 30;105(7):377-82
pubmed: 27005731
Clin Neurophysiol. 2012 Apr;123(4):640-1
pubmed: 22000334
Mov Disord. 2010 Sep 15;25(12):1830-8
pubmed: 20669300
J Neurochem. 2016 Oct;139 Suppl 1:318-324
pubmed: 27401947
Curr Opin Neurobiol. 1996 Dec;6(6):751-8
pubmed: 9000030
Neuron. 2003 Sep 11;39(6):889-909
pubmed: 12971891
Restor Neurol Neurosci. 2015;33(4):521-30
pubmed: 26409410
Curr Top Behav Neurosci. 2016;29:313-332
pubmed: 26475156
Brain Res. 2013 Nov 6;1537:290-302
pubmed: 23998987
Neurology. 2011 Feb 15;76(7):601-9
pubmed: 21321333
Exp Brain Res. 2009 Dec;199(3-4):411-21
pubmed: 19701632
Cereb Cortex. 2015 Jul;25(7):1806-14
pubmed: 24451657
Neurorehabil Neural Repair. 2009 May;23(4):373-81
pubmed: 18978029
Neurophysiol Clin. 2020 Jul;50(3):213-225
pubmed: 32620273
Neuroscience. 2009 Dec 1;164(2):360-9
pubmed: 19729051
Eur J Neurol. 2013 Jan;20(1):5-15
pubmed: 23279439
Prog Neurobiol. 2015 Sep;132:96-168
pubmed: 26209473
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S123-6
pubmed: 26411502
Pharmacol Biochem Behav. 1992 Feb;41(2):343-7
pubmed: 1574523